Generative and agentic artificial intelligence may be positioned to reshape the life sciences and healthcare (LSHC) landscape in 2026 and beyond. However, realizing the technology’s full transformative potential is likely to go beyond simply integrating it into existing workflows. AI’s true transformative power, including predictive, generative, and agentic AI, might only be achieved by organizations able to nurture a collaborative partnership between humans and technology and have a trustworthy and ethical approach to governance and data standards.
There is great optimism about AI’s value throughout the industry, according to Deloitte’s 2026 LSHC Outlook survey. More than 80% of health system and health plan executives expect AI to bring moderate-to-significant value in various areas this year—including clinical activities and back-office functions. Many respondents agreed that AI could lead to better health outcomes, stronger consumer engagement, and streamlined operations.
The technology can also be used to help ensure compliance with regulations and audit requirements. Despite the enthusiasm, nearly half of executives said their organizations are still experimenting with AI—and few have advanced beyond pilots, but the impact and value is in scaling. Life sciences leaders similarly recognize AI’s potential to transform R&D, manufacturing, and commercial models, but only a subset of companies have scaled AI solutions; even fewer report material returns on investment (ROI).
SCALING AND GOVERNANCE
Scaling AI—and achieving a measurable impact—will involve enterprise-wide adoption and ongoing tracking. LSHC organizations operationalizing AI across multiple functions—rather than isolating it in specific departments—could reduce administrative burdens, accelerate decision-making, and enhance outcomes and consumer experiences.
But organizations should have governance in place to track progress. If a pilot isn’t trending toward expected metrics after a reasonable time, it should be reevaluated. In addition, LSHC organizations should look beyond cost savings and margin improvements when measuring AI’s ROI. They should consider the impact on clinical outcomes, consumer experiences, and workforce well-being. Executives should also think about broadening their ROI definition. Cost savings and margin improvement matter, but there are other factors. AI’s true value can show up in:
- Improved clinical outcomes
- Stronger consumer and caregiver experiences
- Workforce enablement and well-being
- Accelerated, data-driven decision-making
Without governance and measurement frameworks capturing these dimensions, organizations risk underestimating AI’s value and misallocating investment. This leads us to the tech value gap.
TRACK VALUE CREATION AND BRIDGE THE TECH GAP
When considering ways to create value and ROI through AI adoption, organizations should ensure supportive governance is in place. If the technology is not driving value or moving toward ROI, pause and reevaluate its use. A recent survey by the Scottsdale Institute and Deloitte highlights a notable disconnect, or “tech value gap,” between what some healthcare leaders say they value in technology and what they actually measure.
While 80% of LSHC executives surveyed agree it is important to assess technology’s impact, many still focus on easy-to-quantify financial metrics like implementation costs and immediate savings, and less on broader benefits—such as clinical quality, patient experience, workforce productivity, and even brand reputation. Technology has become so integral to healthcare strategic success that one leading health system’s leadership team modeled the impact of technology’s absence to demonstrate its imperative and impact.
In health’s next era, the LSHC organizations most likely to succeed will be those that consistently earn and protect consumer trust, deliver personalized and high-value experiences at scale, and shift from episodic treatment to a lifelong relationship model—collaborating and cocreating with consumers across prevention, diagnosis, care, and ongoing wellness.
CONSUMERS ARE TAKING CHARGE, TAPPING AI FOR HELP
Rising costs, access challenges, and eroding trust are accelerating an industry shift: Consumers are stepping into the driver’s seat. They are making more decisions, directing their care journeys, and expecting the system to respond and meet them where they are.
Generative AI, advanced digital platforms, and a growing suite of innovative technologies are beginning to revolutionize how they engage with healthcare. According to a recent Deloitte survey, a growing number of consumers now expect:
- Personalized digital dialogues with clinicians
- Integrated, omnichannel experiences
- Transparent use of personal health data
- Demonstrated value in exchange for data sharing
The ability to respond to changing consumer expectations could be an opportunity for LSHC organizations or it could expand the disconnect between consumers and these organizations. Meeting rising consumer expectations is a strategic inflection point for LSHC organizations: Respond decisively and you can strengthen loyalty and growth. Lag behind and the trust-and-engagement gap will widen, putting demand, share, and channel relevance at risk.
Personal health data has become a form of currency. Consumers are increasingly vocal in demanding transparency around how their data is used; they expect clear benefits in return. LSHC organizations should demonstrate not only how they protect and use patient information, but in how data sharing can translate into tangible health outcomes and consumer value.
A central industry question is whether AI and other digital technologies can help reduce reliance on medical interventions by fostering health and well-being. The trend toward “deprescribing” and addressing chronic disease at its root is gaining traction. Technology can now detect health issues earlier, even at pre-symptomatic stages. It can close care gaps and empower individuals to manage health through wearables, personal devices, and data-driven insights. AI-enabled nudges can support treatment adherence, encourage healthy choices, and help prevent future complications.
There is an economic opportunity to address consumer affordability and system healthcare costs by addressing care gaps, coordinating care, designing systems and incentives to reward health promotion, prevention, early detection, and other proactive measures.
FINAL THOUGHTS
Despite the optimism and pilot activity, fully realizing AI’s benefits will likely involve organizations scaling beyond departmental silos, rigorously measuring value beyond immediate financials, and intentionally cultivating consumer trust. In this landscape, organizations able to operationalize AI enterprise-wide, foster transparent and meaningful use of personal data, and emphasize personalized, preventive care are likely to lead the way. As consumers increasingly assert control over their health journeys, the organizations equipped to deliver proactive, data-driven, and trustworthy experiences are likely to set new standards for value, relevance, and impact in health’s next era.
Jay Bhatt is managing director of the Deloitte Center for Health Solutions Deloitte Services LP.